The DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.
Belantamab Mafodotin, Bortezomib, and Dexamethasone for Multiple Myeloma
Abstract
BACKGROUND: Belantamab mafodotin had single-agent activity in patients with relapsed or refractory multiple myeloma, a finding that supports further evaluation of the agent in combination with standard-care therapies. METHODS: In this phase 3, open-label, randomized trial, we evaluated belantamab mafodotin, bortezomib, and dexamethasone (BVd), as compared with daratumumab, bortezomib, and dexamethasone (DVd), in patients who had progression of multiple myeloma after at least one line of therapy. The primary end point was progression-free survival. Key secondary end points were overall survival, response duration, and minimal residual disease (MRD)-negative status. RESULTS: In total, 494 patients were randomly assigned to receive BVd (243 patients) or DVd (251 patients). At a median follow-up of 28.2 months (range, 0.1 to 40.0), median progression-free survival was 36.6 months (95% confidence interval [CI], 28.4 to not reached) in the BVd group and 13.4 months (95% CI, 11.1 to 17.5) in the DVd group (hazard ratio for disease progression or death, 0.41; 95% CI, 0.31 to 0.53; P<0.001). Overall survival at 18 months was 84% in the BVd group and 73% in the DVd group. An analysis of the restricted mean response duration favored BVd over DVd (P<0.001). A complete response or better plus MRD-negative status occurred in 25% of the patients in the BVd group and 10% of those in the DVd group. Grade 3 or higher adverse events occurred in 95% of the patients in the BVd group and 78% of those in the DVd group. Ocular events were more common in the BVd group than in the DVd group (79% vs. 29%); such events were managed with dose modifications, and events of worsening visual acuity mostly resolved. CONCLUSIONS: As compared with DVd therapy, BVd therapy conferred a significant benefit with respect to progression-free survival among patients who had relapsed or refractory multiple myeloma after at least one line of therapy. Most patients had grade 3 or higher adverse events. (Funded by GSK; DREAMM-7 ClinicalTrials.gov number, NCT04246047; EudraCT number, 2018-003993-29.).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Two recent phase III studies have shown significant benefit with belantamab (Table 9), and hence it is likely the drug will be reapproved in the near future with better recommendations for dosing and dose frequency.162,163”
From Multiple myeloma: 2024 update on diagnosis, risk-stratification, and management (2024) · cites this paper as [162]
In the citing paper
“The proportion of patients over age 75 years or with an Eastern Cooperative Oncology Group performance status score of 2 were also small but consistent with results reported in studies of similar populations;5,26,28,33 a progression-free survival benefit was still observed with Tec-Dara in these subgroups.”
From Teclistamab plus Daratumumab in Relapsed or Refractory Multiple Myeloma (2026) · cites this paper as [28]
In the citing paper
“Although grade ≥3 infections have been reported in up to half of patients receiving belantamab mafodotin, along with high incidences of ocular toxicity, regular ophthalmic monitoring, dose modifications, and supportive care can inform management decisions.26,28”
From Teclistamab plus Daratumumab in Relapsed or Refractory Multiple Myeloma (2026) · cites this paper as [28]
Citations
Cites
Kumar, S., Paiva, B., Anderson, K. C., Durie, B., Landgren, O., Moreau, P., Munshi, N., Lonial, S., Bladé, J., Mateos, M.-V., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(16)30206-6 · Cited by 3,061
Self-citationMoreau, P., Attal, M., Hulin, C., Arnulf, B., Belhadj, K., Benboubker, L., Béné, M. C., Broijl, A., Caillon, H., Caillot, D., et al. (2019) · The Lancet · doi:10.1016/s0140-6736(19)31240-1 · Cited by 967
Cilta-cel or Standard Care in Lenalidomide-Refractory Multiple Myeloma.
San-Miguel, J., Dhakal, B., Yong, K., Spencer, A., Anguille, S., Mateos, M.-V., Fernández de Larrea, C., Martínez-López, J., Moreau, P., Touzeau, C., et al. (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2303379 · Cited by 827
Self-citationLonial, S., Lee, H. C., Badros, A., Trudel, S., Nooka, A. K., Chari, A., Abdallah, A.-O., Callander, N., Lendvai, N., Sborov, D., et al. (2020) · The Lancet Oncology · doi:10.1016/s1470-2045(19)30788-0 · Cited by 812
Self-citationTefferi, A., Rumi, E., Finazzi, G., Gisslinger, H., Vannucchi, A. M., Rodeghiero, F., Randi, M. L., Vaidya, R., Cazzola, M., Rambaldi, A., et al. (2013) · Leukemia · doi:10.1038/leu.2013.163 · Cited by 700
Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma.
Sonneveld, P., Dimopoulos, M. A., Boccadoro, M., Quach, H., Ho, P. J., Beksac, M., Hulin, C., Antonioli, E., Leleu, X., Mangiacavalli, S., et al. (2024) · New England Journal of Medicine · doi:10.1056/nejmoa2312054 · Cited by 599
Self-citationTai, Y.-T., Mayes, P. A., Acharya, C., Zhong, M. Y., Cea, M., Cagnetta, A., Craigen, J., Yates, J., Gliddon, L., Fieles, W., et al. (2014) · Blood · doi:10.1182/blood-2013-10-535088 · Cited by 484
Mateos, M.-V., Cavo, M., Blade, J., Dimopoulos, M. A., Suzuki, K., Jakubowiak, A., Knop, S., Doyen, C., Lucio, P., Nagy, Z., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(19)32956-3 · Cited by 444
Self-citationNajean, Y., & Rain, J.-D. (1997) · Blood · doi:10.1182/blood.v90.9.3370 · Cited by 297
Björkholm, M., Derolf, Å. R., Hultcrantz, M., Kristinsson, S. Y., Ekstrand, C., Goldin, L. R., Andreasson, B., Birgegård, G., Linder, O., Malm, C., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2011.34.7542 · Cited by 245
Cited by
Items 101–200 of 209
Ho, P. J., & Li, E. W. (2025) · Internal Medicine Journal · doi:10.1111/imj.16647 · Cited by 2
Self-citationCAR-T cell therapy for multiple myeloma: An update on the current state and future potential
Pophali, P. A., Rosenblatt, J. M., & Avigan, D. (2025) · Best Practice & Research Clinical Haematology · doi:10.1016/j.beha.2025.101659 · Cited by 2
Identification and transformation of novel targets for immunotherapy in multiple myeloma
Wang, Y., Wang, Y., Ma, J., Jing, H., Liu, L., Qiu, L., & Hao, M. (2025) · Chinese Medical Journal · doi:10.1097/cm9.0000000000003869 · Cited by 2
“[96] In the DREAMM-8 phase III trial, the combination of belantamab mafodotin, pomalidomide, and dexamethasone (BPd) demonstrated superior efficacy compared with the combination of pomalidomide, bortezomib, and dexamethasone (PVd) in lenalidomide-exposed patients with R/RMM who had received at…”
Iimura, Y., Sakai, H., Nakajima, I., Kuroda, S., Nakamura, M., & JASCC Onco Ophthalmology Working Group (2026) · International Journal of Clinical Oncology · doi:10.1007/s10147-026-03096-x · Cited by 1
Antibody–Drug Conjugates and Peptide–Drug Conjugates: Current Understandings and Future Perspectives
Zheng, R., Li, S., Zhang, Z., Niu, M., Fei, J., Zhang, J., Zhou, J., Wu, K., Yi, M., & Li, T. (2026) · MedComm · doi:10.1002/mco2.70897 · Cited by 1
McCurdy, A. B. R., Gul, E., Reece, D. E., Chu, M. P., Jimenez-Zepeda, V. H., Louzada, M., Song, K., Mian, H. S., Sébag, M., White, D. J., et al. (2025) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2025.02.011 · Cited by 2
Kawamura, K., Tsukada, N., Kimura, S., Kako, S., Minakata, D., Enami, T., Hamano, Y., Yamamoto, G., Ota, S., Obara, N., et al. (2025) · Hematological Oncology · doi:10.1002/hon.70129 · Cited by 1
Gavriatopoulou, M., Manganas, S., Ntanasis‐Stathopoulos, I., & Dimopoulos, M. A. (2025) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2025.10.004 · Cited by 1
Self-citationPopat, R., Augustson, B. M., Cannell, P., Stockerl-Goldstein, K. E., Spencer, A. G., Khot, A. S., Nooka, A. K., Patel, N., Kasinathan, R. S., McKeown, A., et al. (2026) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-25-3216 · Cited by 1
“The efficacy and safety profile of the BVd dosing schedule in DREAMM-7 (belantamab mafodotin 2.5 mg/kg every 3 weeks) and dose-modification protocol (9) broadly align with the findings from this study: Differences in efficacy measures such as PFS be-tween these studies likely reflect the more…”
InfluentialSelf-citationLiu, Y., Lee, J. H., Mo, C. C., Salman, T. J., Hossain, S., Midha, S., Nadeem, O., Nicholson, T., Croteau, J., Kazierad, N., et al. (2026) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2026.2646947 · Cited by 3
Chen, Q., Tian, T., Shi, Y. E., Shen, X., Qiu, H. R., Jin, Y., Chen, L., & Guo, R. H. (2026) · The Oncologist · doi:10.1093/oncolo/oyag105 · Cited by 2
Awadallah, C., Zayad, A., Atrash, S., Mazloom, A., Alkharabsheh, O. A., Mewawalla, P., Shah, M. R., Lutfi, F. U., Mahmoudjafari, Z., Mushtaq, M. U., et al. (2026) · Current Oncology · doi:10.3390/curroncol33050249 · Cited by 1
“The therapeutic landscape for MM has evolved substantially over the past two decades with the introduction of proteasome inhibitors (PIs), immunomodulatory drugs (IMiDs), CD38-directed monoclonal antibodies, and, more recently, T-cell redirecting therapies [8–11].”
Self-citationBelantamab mafodotin, a BCMA-directed antibody-drug conjugate for multiple myeloma
Samuel, M., Flores, M. S., Lowy, J. A., Rogers, M. F., Avigan, Z. M., Rattu, M. A., & Richter, J. R. (2026) · Future Oncology · doi:10.1080/14796694.2026.2700028 · Cited by 1
Immunotherapy in cancer: Mechanisms and strategies to overcome resistance
Yang, H., Yang, Z., Wang, X., Patel, H. H., Wu, Z., Ashby, C. R., Wang, W., & Chen, Z. (2026) · Drug Resistance Updates · doi:10.1016/j.drup.2026.101447 · Cited by 1
Peck, O. H., McCoubrey, A., Snowden, J. A., Wechalekar, A. D., Travers, J., Lees, J. S., Petrie, M. C., & Lang, N. N. (2026) · Open Heart · doi:10.1136/openhrt-2026-004240 · Cited by 1
Treatment Decisions in Multiple Myeloma
Mouhieddine, T. H., & Anderson, K. C. (2026) · New England Journal of Medicine · doi:10.1056/nejmra2605253 · Cited by 1
Matsumura, N., & Mandai, M. (2025) · International Journal of Clinical Oncology · doi:10.1007/s10147-025-02811-4 · Cited by 1
Treatment of Early Relapse: Non-CAR T Cells
Ntanasis‐Stathopoulos, I., & Dimopoulos, M. A. (2024) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/s2152-2650(24)00361-6
Self-citationHow to rescue a DreaMM deferred …
Joseph, N. S., & Lonial, S. (2024) · Med · doi:10.1016/j.medj.2024.07.027
Kumar, A. D., Chung, A., Pan, D., & Chari, A. (2024) · The Hematologist · doi:10.1182/hem.v21.6.202467
Sunami, K., Iida, S., Tsukada, N., Fujii, T., Kato, H., Fukushima, R., Wakabayashi, S., Nakano, H., Roy–Ghanta, S., & Kremer, B. E. (2024) · International Journal of Hematology · doi:10.1007/s12185-024-03889-8
Self-citationSayyaparaju, M. V. (2024) · Open Journal of Clinical and Medical Case Reports · doi:10.52768/2379-1039/2291
Qiao, S., Song, Y. S., Dong, X., Chen, X., Meng, H., Long, H., Gong, J., Wang, Y., Liu, Y., Liu, Y., et al. (2025) · SSRN Electronic Journal · doi:10.2139/ssrn.5075166
Mieloma Múltiplo: Biologia, Diagnóstico e Tratamento
Tabak, D. G. (2024) · Anais da Academia Nacional de Medicina · doi:10.52130/27639878-aanm2024v195n2p43-61
Phua, C. W. T., & McCulloch, S. (2025) · Canadian Hematology Today · doi:10.58931/cht.2025.4s0161
Therapie des multiplen Myeloms – was ist neu und was bleibt?
Kortüm, K. M., Waldschmidt, J. M., & Einsele, H. (2025) · Die Onkologie · doi:10.1007/s00761-024-01675-z
Exploiting macropinocytosis for therapeutic intervention in RAS mutant Multiple MyelomaPreprint
Beals, N., Ramírez, C., Koide, A., Hauser, A. D., Davies, F. E., Koide, S., Morgan, G. J., & Bar‐Sagi, D. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.04.04.647098
Neue Möglichkeiten für die Rezidivtherapie
Hentrich, M., Mertens, L., & Högner, M. (2025) · InFo Hämatologie + Onkologie · doi:10.1007/s15004-025-0954-5
Luna, J., d'Estrube, T., Jacobsen, A., Lehne, M., Wellmann-Pichler, B., Mevius, A., & Dornig, S. (2025) · Annals of Hematology · doi:10.1007/s00277-025-06427-6
Hematological Treatments and Disease Modifying Therapies in AL Cardiac Amyloidosis
Lebel, E., Even‐Zohar, N. G., & Gatt, M. E. (2025) · Springer eBooks · doi:10.1007/978-3-031-88342-2_14
Self-citationTumultuous Development of Venetoclax in t(11;14) Multiple Myeloma
Kaiser, M., & Cliff, E. R. S. (2025) · Journal of Clinical Oncology · doi:10.1200/jco-25-01088
Gay, F., Marchetti, E., & Bertuglia, G. (2025) · Kompass Onkologie · doi:10.1159/000547999
Multiples Myelom: Hochrisikomyelom Therapiestrategien und neue Ansätze
Artzenroth, C., Al-Bazaz, M., Kosch, R., Schaefers, C., Weisel, K. C., & Leypoldt, L. B. (2025) · Trillium Krebsmedizin · doi:10.47184/tk.2025.05.2
EHA 2025 - Viel Neues in der Hämatoonkologie
Kretzschmar, A. (2025) · Onkologische Welt · doi:10.1055/a-2681-4741
Belantamab mafodotin for the treatment of multiple myeloma
Oriol, A., Ibarra, G., Loscos, J., & Abril, L. (2025) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2025.2576502
“%) were substantially different [43,46].”
Self-citationQiao, S., Long, H., Xu, D., Meng, H., Gong, J., Wang, Y., Liu, Y., Zhang, H., & Mao, L. (2025) · Results in Chemistry · doi:10.1016/j.rechem.2025.102819
Updated recommendations for diagnosis and treatment of multiple myeloma in Switzerland
Bertschinger, M., Auner, H. W., Ballová, V., Ortiz, C. D. R., Driessen, C., Gerull, S., Heim, D. A., Jeker, B., Lerch, E., Müller, R., et al. (2025) · Swiss Medical Weekly · doi:10.57187/s.4252
Gehlert, C. L., Schewe, D. M., Klausz, K., Krohn, S., Winterberg, D., Vogiatzi, F., Boje, A. S., Baum, N., Könecke, M., Lux, A., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.10.30.684608
“…combination of ADC such as gemtuzumab ozogamicin or belantamab mafodotin with chemotherapy or immunomodulatory drugs showed synergistic potential and may also represent further strategies to achieve long-lasting therapeutic activity in a higher proportion of patients treated with CD7-ADC [55-57].”
Mainou, M., Alsadhan, M., Tsapa, K., Visram, A., Mian, H. S., Popat, R., Mai, E. K., Chakraborty, R., Hadidi, S. A., Mohan, M., et al. (2025) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djaf326
“41,42 In addition, some standard care regimens are now performing better than their historical pivotal trials, potentially due to better supportive care and improved performance status and organ function of patients due to more effective prior treatments.”
Cancer Drug Response Prediction Based on Graph Neural Networks and Cross-Attention
Zhang, J., & Zhang, Y. (2025) · International Joint Conference on Neural Networks (IJCNN) · doi:10.1109/ijcnn64981.2025.11229164
“Bortezomib [19] has the lowest predicted average IC50 value among the groups, leading the conclusion that Bortezomib is effective in cancer treatment.”
Dreaming of a better future: drug development in myeloma
Parikh, R., & Lonial, S. (2025) · Blood Advances · doi:10.1182/bloodadvances.2024015740
Shustik, J. (2025) · Canadian Hematology Today · doi:10.58931/cht.2025.4379
Characteristics and utilization of the three BCMA-targeted therapies in multiple myeloma
Mihara, K., & Miyama, T. (2025) · International Journal of Hematology · doi:10.1007/s12185-025-04128-4
“Thrombocytopenia occurred in 56% (BVd) and 35% (DVd) [7].”
Sunami, K., Handa, H., Ichii, M., Ikezoe, T., Suzuki, K., Yamaguchi, Y., Yonekawa, T., Endo, A., Nakano, H., Lewis, E., et al. (2026) · International Journal of Hematology · doi:10.1007/s12185-025-04150-6
Self-citationKęska, M., Platschek, M., Tuleja, A. B., Drabik, M., Kosmulska, J., Dybalska, K., Sikora, M., Kolano, S. W., Nowak, J., Szkarłat, K. J., et al. (2025) · International Journal of Innovative Technologies in Social Science · doi:10.31435/ijitss.4(48).2025.4258
Mansour, R. A., Green, K. M., Graf, C., Chang, M., Magee, G., Davis, J. A., Zayad, A., Ahmed, N., Mushtaq, M. U., Ouchveridze, E., et al. (2026) · European Journal Of Haematology · doi:10.1111/ejh.70077
“[35].”
Self-citationLuo, Y., Jiang, T., & Liu, L. (2026) · Hematology · doi:10.1080/16078454.2026.2613508
Availability of pharmacological treatments for multiple myeloma in Spain
Garrido‐Alejos, G., Feliu, A., Gay-Pérez, D., Pontes, C., & Vallano, A. (2026) · The European Journal of Health Economics · doi:10.1007/s10198-025-01883-3
Kang, Y., Liu, Q., Liu, Q., Xie, W., Sun, C., & Mei, H. (2026) · Blood Cancer Journal · doi:10.21203/rs.3.rs-8750940/v1
Bayly-McCredie, E., Prince, H. M., Yannakou, C. K., Fiorenza, S., & Wisniowski, B. (2026) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2026.2634055
“…ADC belantamab mafadotin in combination with bortezomib and dexamethasone has demonstrated improved efficacy over daratumumab with bortezomib and dexamethasone when used as early as second-line therapy, demonstrating the value of an anti-BCMA strategy early in the management of myeloma [119].”
When Outcomes With Bispecifics Start to Resemble CAR T Cells: Lessons From MajesTEC-3
Pan, D., Kumar, A., Lipof, J. J., Chung, A., & Chari, A. (2026) · The Hematologist · doi:10.1182/hem.v23.2.202624
Choosing Wisely in First Relapse of Multiple Myeloma: Expert Insights on Treatment Selection
Hadidi, S. A., Costello, C. L., Costa, L. J., Dhakal, B., Georges, P., Gajra, A., Lin, Y., Bhargava, R. S., Paner-Straseviciute, A., & Vij, R. (2026) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2026.03.009 · Cited by 1
Breaking new ground with antibody-drug conjugates in myeloma
Usmani, S. Z. (2026) · Blood · doi:10.1182/blood.2025032443
In reply: Why selinexor remains a subpar option?
Mohyuddin, G. R., & Meirson, T. (2026) · The Oncologist · doi:10.1093/oncolo/oyag113
Richter, J. R., Davis, M., & Chai, Y. (2026) · The Oncologist · doi:10.1093/oncolo/oyag112
Papathanasiou, T., Chen, X., Carreno, F., McKeown, A., Roy–Ghanta, S., Eccersley, L., Kasinathan, R. S., Patel, N., & Ferron‐Brady, G. (2026) · British Journal of Cancer · doi:10.1038/s41416-026-03437-7
Self-citationCorradini, P., Musto, P., Galeone, C., Mariani, P., Resci, F., & Cavo, M. (2026) · Leukemia Research · doi:10.1016/j.leukres.2026.108230
Self-citationFujisaki, T., Kubo, K., Hiramatsu, Y., Ogawa, R., Yonekawa, T., Endo, A., Nakano, H., Lee, J., Eccersley, L., Baig, H., et al. (2026) · International Journal of Hematology · doi:10.1007/s12185-026-04211-4
“The proportion of patients who achieved MRD negativity plus CR or better was also higher in the BVd group than the DVd group in the global cohort [13].”
InfluentialSelf-citationRole B-cell maturation antigenu v léčbě mnohočetného myelomu
Vilímová, K., Kušnierová, P., Mihályová, J., & Hájek, R. (2026) · Klinická biochemie a metabolismus · doi:10.61568/kbm.2026.001
Can Belantamab mafodotin cause macro LDH?
Hakakian, L., Shragai, T., Trestman, S., Cohen, Y. C., Katz, B., Arafat, N., Hassoun, E., Melamed, N., & Avivi, I. M. (2026) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2026.2649877
Advances in the Treatment of Multiple Myeloma
余, 佳. (2026) · Advances in Clinical Medicine · doi:10.12677/acm.2026.1641697
Advances in natural killer cell immunotherapy for hematologic malignancies
Hu, H., Xiong, Y., Xia, M., & Sheng, L. (2026) · Cancer Biology & Therapy · doi:10.1080/15384047.2026.2658896
Case Report: Corneal Toxicity in Antibody-Drug Conjugate
Skoog, W. (2025) · Clinical Insights in Eyecare · doi:10.66574/001c.142745
Ocular side effects of antibody–drug conjugates for cancer treatment
Heitz, F., Scheider, A., Harter, P., & Groeben, M. (2026) · Deutsches Ärzteblatt international · doi:10.3238/arztebl.m2026.0060
Li, H., Xia, Q., Yu, M., Lv, Y., Xiao, J., Guo, X., Dong, K., Zhou, Y., Zhong, L., Wang, T., et al. (2026) · Science China Life Sciences · doi:10.1007/s11427-025-3227-0
“…cytotoxicity while minimizing systemic exposure (Aggarwal et al., 2022; Chakraborty et al., 2021; Figueroa-Vazquez et al., 2021; Huang et al., 2022; Hungria et al., 2024; Kaufman et al., 2022; Kelly et al., 2021; Lee et al., 2021; Leong et al., 2023; Li et al., 2023a; Xing et al., 2021; Yu et al.,…”
Bergantim, R., Freitas, J. G., Gonçalves, C., Martins, H., Marques, H., Coelho, H. G. B., Seabra, P., Roque, A. I., Tavares, M., Pinto, P., et al. (2026) · Hematology Reports · doi:10.3390/hematolrep18030034
“More recently, bispecific antibodies [13,14], CAR T cells [15,16] or even antibody–drug conjugates (ADCs), such as belantamab mafodotin [17–19] have proven the added potential benefits of novel therapeutics in improving the clinical outcomes in MM patients.”
Chen, X., Hakim, S., Lien, Y. T., Dimopoulos, M. A., Lichtman, E. I., Min, C., Chng, W. J., Ailawadhi, S., Delimpasi, S., Hrabrick, E., et al. (2026) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2026.05.009
Self-citationClinical implications of minimal residual disease monitoring in multiple myeloma
Yoroidaka, T. (2026) · International Journal of Hematology · doi:10.1007/s12185-026-04229-8
“The proportion of patients who achieved both VGPR or better and MRD negativity (NGS sensitivity, 10 −5 ) was 39% in the Bela-Vd group and 17% in the DVd group [53].”
High-Risk Multiple Myeloma: Redefining Risk and Rethinking Therapy
Morgan, G. J., Lee, D. D., Joseph, N. S., Lonial, S., Rodríguez‐Otero, P., & San-Miguel, J. (2026) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk-26-517494
Redefining Early Relapse in Multiple Myeloma — Time to Change the Rules
Mateos, M. (2026) · New England Journal of Medicine · doi:10.1056/nejme2605404
Self-citationAntibody–drug conjugates in hematologic malignancies
Patel, K., Strickland, S. A., & Lee, H. C. (2026) · Cancer · doi:10.1002/cncr.70421
Hansen, D. K., Mateos, M., & Costa, L. J. (2026) · Blood Advances · doi:10.1182/bloodadvances.2026019699
“18,19,21,31 As monotherapy, belamaf did not show superiority over pomalidomide and dexamethasone in the DREAMM-3 trial, in a population with ≥ 2 prior LOT (median, 4), including 71% lenalidomide refractoriness and 34% anti-CD38 mAb refractoriness.”
Self-citationCarreño, F. O., van Noort, M., Taylor, A. B., Zeiser, S., Papathanasiou, T., Post, T. M., Lien, Y. T., Ho, Y. L., & Ferron‐Brady, G. (2026) · CPT Pharmacometrics & Systems Pharmacology · doi:10.1002/psp4.70276
Bertuglia, G., Nicola, A. D., Gay, F., Larocca, A., Bruno, B., & D’Agostino, M. (2026) · Frontiers in Oncology · doi:10.3389/fonc.2026.1822419
Camargo, C., Corona-Arias, C. A., Sandoval, Y. C. C., Ballesteros, W. G. G., Agudelo, D. S. J., & Romero, G. I. T. (2026) · Journal of Applied Hematology · doi:10.4103/joah.joah_23_26
Richter, J. R., Efebera, Y. A., Yimer, H. A., Shukla, P., Kapetanakis, V., Purser, M. F., Boytsov, N. N., & Ballew, N. L. (2026) · American Journal of Hematology · doi:10.1002/ajh.70408
Liang, T., Li, J., & Xu, C. (2026) · Therapeutic Innovation & Regulatory Science · doi:10.1007/s43441-026-00967-3
Innate immune dysregulation in multiple myeloma: molecular basis and mechanistic interventions
Wang, G., Gao, H., Xie, T., & Zi, F. (2026) · International Immunopharmacology · doi:10.1016/j.intimp.2026.116996
Mina, R., Terpos, E., Cani, L., Nooka, A. K., Trudel, S., Voorhees, P., Mian, H. S., Dhakal, B., Usmani, S. Z., Richter, J., et al. (2026) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2026.06.014
Self-citationAdvances in the Treatment of Newly Diagnosed Multiple Myeloma: Current Status and Future Directions
Liu, Y. (2026) · healthbook TIMES Oncology Hematology · doi:10.36000/hbt.oh.2026.28.209 · Cited by 1
Practical recommendations for infectious prophylaxis and vaccination in multiple myeloma patients
Bergantim, R., Roque, A. I., Jorge, A., Freitas, J. G., Miranda, M. T., Nunes, M., Ionita, A., Bernardo, P. V., Vieira, J., Aguiar, E. V., et al. (2026) · Frontiers in Medicine · doi:10.3389/fmed.2026.1847793 · Cited by 1
Top advances of the year: Bispecific antibodies in early lines of therapy in multiple myeloma
Worth, H. A., & Costa, L. J. (2026) · Cancer · doi:10.1002/cncr.70519
Elranatamab: A novel B-cell maturation T-cell engager
Hossain, S., & Bianchi, G. (2026) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2026.2694852
“13,14 These studies have allowed for the return of belantamab after a voluntary withdrawal.”
Schinas, G., Voutsinas, P.-M., Stefanou, D., Stafylidis, C., Gkoufa, A., Ziogas, D. C., Diamantopoulos, P. T., Gogas, H., & Anastasopoulou, A. N. (2026) · Current Oncology Reports · doi:10.1007/s11912-026-01804-4
Potential of new BCMA-targeting therapies in overcoming resistance in multiple myeloma
Sra, M. S., & Kumar, S. (2026) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2026.2703858
Revolutionizing 2L+ Myeloma: A Podcast on the New Era of BCMA-Targeted Bispecific Antibody Therapies
Mina, R., Doyle, M., & Nooka, A. K. (2026) · Advances in Therapy · doi:10.1007/s12325-026-03715-z
More options, more questions in the management of early relapsed and/or refractory multiple myeloma
Tan, C. R., & Mailankody, S. (2026) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-026-01191-6
Luqmana, H. P., Ashariati, A., Savitri, M., Rachma, B., & Sutanto, H. (2026) · Immunological Investigations · doi:10.1080/08820139.2026.2713194
2026 Myeloma Treatment Guidelines of the Turkish Myeloma Study Group
Beksaç, M., Mastanzade, M. G., Değirmenci, B. B., Oluk, B., Sağlam, B., Özlük, D. Ö., Cengiz, E., Alhan, F. N., Dikici, H. Z., Uygun, K. Y., et al. (2026) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2026.08.008 · Cited by 1
Philipovskiy, A. V., Shurmur, S. W., & Abid, M. B. (2026) · Cancers · doi:10.3390/cancers18162652
Multiple Myeloma: 2026 Update on Diagnosis, Risk‐Stratification and Management
Rajkumar, S. V. (2026) · American Journal of Hematology · doi:10.1002/ajh.70475 · Cited by 5
Huang, C., Zhang, X. L., Teng, Y., Zhang, Z., Wang, B., Gu, P., Deng, X., Wang, D., Xiao, H., Zou, L., et al. (2026) · International Journal of Nanomedicine · doi:10.2147/ijn.s628321
“38,145,146 Firestone et al reported that loss of BCMA expression can become a shared resistance mechanism among BCMA CAR-T therapy, belantamab, and BCMA bispecific antibodies.”
Kyriakou, C. A., Forde, K., Cocks, K., Scouler, E., Petranovia, D., Lehmann, J., Oerlemans, S., Ntanasis‐Stathopoulos, I., Constantinou, V., Nielsen, L. K., et al. (2026) · Research Square · doi:10.21203/rs.3.rs-10687466/v1
Bridging Innovation in Multiple Myeloma Care: A Review of Novel Therapies
Michelly De Castro, D., & Ow, K. (2026) · Journal of the Advanced Practitioner in Oncology · doi:10.6004/jadpro.2026.17.7.25
Zhang, X., Xing, X., Wang, Z., Wang, K., Hua, Y., Zhang, L., & Dong, X. (2026) · PharmacoEconomics - Open · doi:10.1007/s41669-026-00681-8
Ahrens, R., Yousefi, B., Laubach, N. C., Truger, M. S., Haferlach, T., Heins, S., Teipel, R., Mitsiades, C. S., Papadopoulos, E., Ahrens, K., et al. (2026) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2026.09.010
Kul, S., Eminoglu, H., Altinoz, B., Zorlu, T., Candır, B. A., Ulaş, T., & Dal, M. S. (2026) · Pharmaceutics · doi:10.3390/pharmaceutics18111431
Schaefers, C., Khandanpour, C., Hänel, M., Kull, M., Alsdorf, W. H., Kamili, A., Kosch, R., Krüger, W., Bohl, S., Mai, E. K., et al. (2026) · BMC Cancer · doi:10.1186/s12885-026-16905-3
“These data underline the potency of belantamab mafodotin combinations in early relapse [21].”
InfluentialIdentification of broadly tumour-reactive γδ TCRs from multiple myeloma
Paul, M. S., Hendrikse, L. D., Ying, F., Snow, B. E., Luo, P., Helke, S., Smith, L. K., Hilal, A., Abelman, D. D., Ramamurthy, N., et al. (2026) · Nature · doi:10.1038/s41586-026-11055-9
Proteostasis as a Therapeutic Backbone: Proteasome Inhibitors and Emerging Regimens
Song, Y., Theprungsirikul, P., Gullà, A., & Anderson, K. C. (2026) · The Cancer Journal · doi:10.1097/ppo.0000000000000852
Metadata
- Authors
- Hungria, V., Robak, P., Hus, M., Zherebtsova, V., Ward, C., Ho, P. J., Ribas de Almeida, A. C., Hajek, R., Kim, K., Grosicki, S., Sia, H., Bryant, A., Pitombeira de Lacerda, M., Aparecida Martinez, G., Sureda Balarí, A. M., Sandhu, I., Cerchione, C., Ganly, P., Dimopoulos, M., Fu, C., Garg, M., Abdallah, A.-O., Oriol, A., Gatt, M. E., Cavo, M., Rifkin, R., Fujisaki, T., Mielnik, M., Pirooz, N., McKeown, A., McNamara, S., Zhou, X., Nichols, M., Lewis, E., Rogers, R., Baig, H., Eccersley, L., Roy-Ghanta, S., Opalinska, J., & Mateos, M.-V.
- Affiliations
- From Clinica São Germano (V.H.) and Hospital das Clínicas and Instituto do Câncer do Estado de São Paulo, Universidade de São Paulo (G.A.M.), São Paulo, Centro de Pesquisa e Ensino em Saúde de Santa Catarin, Florianópolis (A.C.R.A.), and Universidade da Região de Joinville and Centro de Hematologia e Oncologia, Joinville (M.P.L.) — all in Brazil; Medical University of Lodz, Lodz (P.R.), Medical University of Lublin, Lublin (M.H., M.M.), and the Medical University of Silesia, Katowice (S.G.) — all in Poland; Gorodskaya Klinicheskaya Bol’nitsa Imeni Saint Petersburg Botkina, Moscow (V.Z.); the Royal North Shore Hospital (C.W.) and Liverpool Hospital (A.B.), Sydney, Royal Prince Alfred Hospital and University of Sydney, Camperdown, NSW (P.J.H.), and Pindara Private Hospital, Gold Coast, QLD (H.S.) — all in Australia; the Department of Hematooncology, University Hospital Ostrava, and Faculty of Medicine, University of Ostrava, Ostrava, Czech Republic (R.H.); Sungkyunkwan University and Samsung Medical Center, ...
- Medical University of Lublin (PL)
- ORCID
- Robak, Pawel
- Hus, Marek
- Ho, P. Joy
- Grosicki, Sebastian
- Bryant, Adam
- Pitombeira de Lacerda, Marcelo
- Sandhu, Irwindeep
- Cerchione, Claudio
- Ganly, Peter
- Dimopoulos, Meletios
- Fu, Chengcheng
- Garg, Mamta
- Abdallah, Al-Ola
- Oriol, Albert
- Gatt, Moshe E.
- Rifkin, Robert
- Mielnik, Michał
- Pirooz, Nick
- McKeown, Astrid
- McNamara, Simon
- Nichols, Maureen
- Rogers, Rachel
- Eccersley, Lydia
- Mateos, María-Victoria
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2024-08-01
- Volume
- 391
- Issue
- 5
- Pages
- 393-407
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W4399257301
- Semantic Scholar
- 2132fd7eacf293858f040cac026dbc0e4e2031e8
- Cited by
- 199
- References
- 28
- Citations by year
- 2026: 83 · 2025: 96 · 2024: 20
- FWCI
- 61.73
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- DIGITAL.CSIC (Spanish National Research Council (CSIC)) (acceptedVersion)
- Archivio istituzionale della ricerca (Alma Mater Studiorum Università di Bologna) (submittedVersion)
- Funders
- GlaxoSmithKline
- Topics
- Health Sciences › Medicine › Hematology › Multiple Myeloma Research and Treatments
- Life Sciences › Immunology and Microbiology › Immunology › Monoclonal and Polyclonal Antibodies Research
- Health Sciences › Medicine › Hematology › Chronic Lymphocytic Leukemia Research
- Keywords
- belantamab mafodotin, daratumumab, bortezomib, dexamethasone, relapsed/refractory multiple myeloma, progression-free survival, overall survival, minimal residual disease, ocular adverse effects, visual acuity, combination therapy, monoclonal antibody-drug conjugate, proteasome inhibitors, immunomodulators
- MeSH terms
- Bortezomib, Progression-Free Survival, Adult, Aged, Aged, 80 and over, Antibodies, Monoclonal, Antineoplastic Combined Chemotherapy Protocols, Dexamethasone, Female, Humans, Male, Middle Aged, Multiple Myeloma, Survival Analysis, Neoplasm, Residual, Disease Progression, Kaplan-Meier Estimate, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.